Scitegrity supported drug receives FDA approval

Catalyst Pharmaceuticals

Scitegrity supported drug receives FDA approval

The drug to treat Lambert-Eaton myasthenic syndrome (LEMS) in adults approved. Drug Abuse Potential assessments supported by Scitegrity


Catalyst Pharma have announced the FDA have approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Scitegrity supported Catalyst Pharma’s NDA submission by providing Drug Abuse Potential expertise and assessments for use in the NDA submission.

LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.